Elimination of frequent vital sign monitoring in patients receiving paclitaxel.
Thomas
M
M
Sarah Cannon Cancer Center, Nashville, TN, USA.
D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects* / Q000627:therapeutic use; D004342:Drug Hypersensitivity / Q000517:prevention & control*; D006801:Humans; D008991:Monitoring, Physiologic / Q000451:nursing*; D017239:Paclitaxel / Q000009:adverse effects* / Q000627:therapeutic use
D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel